TY  - JOUR
AU  - Lopez-Beltran, Antonio
AU  - Henriques, Vanessa
AU  - Cimadamore, Alessia
AU  - Santoni, Matteo
AU  - Cheng, Liang
AU  - Gevaert, Thomas
AU  - Blanca, Ana
AU  - Massari, Francesco
AU  - Scarpelli, Marina
AU  - Montironi, Rodolfo
PY  - 2018
DO  - 10.3389/fonc.2018.00456
SN  - 2234-943X
UR  - http://hdl.handle.net/10668/13205
T2  - Frontiers in oncology
AB  - The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug...
LA  - en
PB  - Frontiers Research Foundation
KW  - PD-L1
KW  - RCC subtypes
KW  - Immunological biomarker
KW  - Immunotherapy
KW  - Predictive biomarker
KW  - Renal cell carcinoma
KW  - Tumor mutation load
KW  - Carcinoma, renal cell
KW  - Prognosis
KW  - Immune checkpoint inhibitors
KW  - Programmed cell death 1 receptor
KW  - Immunohistochemistry
KW  - Kidney neoplasms
KW  - Biomarkers
KW  - Immunotherapy
TI  - The Identification of Immunological Biomarkers in Kidney Cancers.
TY  - research article
VL  - 8
ER  -